Disparities in Respiratory Syncytial Virus Vaccine Uptake in the Medicare Fee-for-Service Population During 2023-2024 Season.

ABSTRACT:

Background

Respiratory syncytial virus (RSV) is a common cause of acute respiratory illness and can lead to serious morbidity and mortality in older adults. With the Food and Drug Administration approval and the Centers for Disease Control and Prevention (CDC) recommendation of RSV vaccines in 2023, this study describes first season vaccine uptake in adults ≥ 65 years.

Methods

In a retrospective cohort of 100% Medicare Fee-for-Service (FFS) beneficiaries with Part D coverage, we examined RSV vaccination claims data from July 2023 to June 2024. Cumulative RSV vaccine uptake rates were evaluated by demographic, socioeconomic, and health characteristics, along with evaluation of vaccine coadministration. We reported descriptive statistics.

Results

Among 15,841,938 Medica

SUBMITTER: Murphy A 

PROVIDER: S-EPMC12554831 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature